Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07331389CT.gov A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin | — | Recruiting | — | — | — |
NCT06564441CT.gov A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity | — | Completed | — | — | — |
NCT06279234CT.gov A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus | — | Completed | — | — | — |
NCT06186622CT.gov A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants | — | Completed | — | — | — |
NCT05445232CT.gov A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | — | Completed | — | — | — |
NCT05247970CT.gov A Study to Assess S-309309 in Healthy and Obese Participants | — | Completed | — | — | — |
NCT04621227CT.gov Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity | — | Completed | — | — | — |
NCT04248335CT.gov Effect of Obesity on Proton Pump Inhibitors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Midazolam (this asset) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Approved | B · 58 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Midazolam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuralgia | — | P4 | BBB · 75 |
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 75 |
| Choledocholithiasis | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Midazolam in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/midazolam-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →